4th Palermo Conference on INNOVATIVE THERAPIES FOR LYMPHOID MALIGNANCIES
Haematologica, Vol 92, Issue 10, 1327-1334 doi:10.3324/haematol.11068
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pigneux, A.
Right arrow Articles by Reiffers, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pigneux, A.
Right arrow Articles by Reiffers, J.

Acute Myeloid Leukemia

Adding lomustine to idarubicin and cytarabine for induction chemotherapy in older patients with acute myeloid leukemia: the BGMT 95 trial results

Arnaud Pigneux, Virginie Perreau, Eric Jourdan, Norbert Vey, Nicole Dastugue, Françoise Huguet, Jean-Jacques Sotto, L. Rachid Salmi, Norbert Ifrah, Josy Reiffers

From Hopital du Haut-Leveque, Pessac (AP, VP, LRS); Hopital Caremeau, Nîmes (EJ); Institut Paoli Calmettes, Marseille (NV); Hopital Purpan, Toulouse (ND, FH); Hopital Michallon, Grenoble (J-JS); Hopital d’Angers, Angers (NI); Institut Bergonié, Bordeaux (JR), France

Correspondence: Arnaud Pigneux, Service des Maladies du Sang, Hopital du Haut-Leveque, Avenue de Magellan, 33604 Pessac Cedex, France. E-mail: arnaud.pigneux{at}chu-bor-deaux.fr

Background and Objectives: Treatment of acute myeloid leukemia (AML) in older patients remains unsatisfactory. The BGMT 95 trial for older patients set out to improve the outcome of these patients by adding a third drug (lomustine) to a 5+7 idarubicin and cytarabine schedule at induction and evaluating intermediate-dose cytarabine as consolidation.

Design and Methods: A multicenter randomized trial was performed comparing induction therapy with idarubicin and cytarabine, 5+7 (IC) to induction therapy with the same drugs plus lomustine (CCNU), 200 mg\m2 orally on day 1 (ICL). Patients in complete remission (CR) were then randomized to receive either maintenance therapy or intensification with intermediate-dose cytarabine and idarubicin followed by maintenance therapy.

Results: Between 1995 and 2001, 364 patients (≥60 years) from ten centers were included. The CR rate was 58% for patients in the IC arm and 67% for patients in the ICL arm (p=0.104). The median overall survival (OS) was 7 and 12 months respectively (p=0.05), but OS at 2 years was not statistically different: 31±7% for patients in the ICL arm vs 24±6% for those in the IC arm. The two post-remission strategies yielded similar results.

Interpretation and Conclusions: Adding lomustine to induction with idarubicin and cytarabine therapy did not statistically improve survival in elderly patients with AML. Adding intermediate-dose cytarabine to consolidation therapy did not improve outcome.

Key words: AML, older patients, lomustine.




This article has been cited by other articles:


Home page
 JCOHome page
T. Prebet, N. Boissel, S. Reutenauer, X. Thomas, J. Delaunay, J.-Y. Cahn, A. Pigneux, B. Quesnel, F. Witz, S. Thepot, et al.
Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup
J. Clin. Oncol., October 1, 2009; 27(28): 4747 - 4753.
[Abstract] [Full Text] [PDF]